Patent · US Active

Lisinopril formulations

US11179434B2 · kind B2 · utility

3Cited by
31References
18Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 5, 2021
Grant dateNov 23, 2021
Priority date
Expiry dateMar 5, 2041

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K47/26
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.